Monthly Archives: February 2020

A longitudinal study shows that findings from a baseline screening colonoscopy were associated with risk of advanced neoplasia within 10 years Continue reading →

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease world-wide, affecting 20-25% of the adult population. In 25% of patients, NAFLD progresses to non-alcoholic steatohepatitis (NASH), which increases the risk for the developme… Continue reading →

Gut microbiota plays a role in the pathophysiology of metabolic diseases which also include nonalcoholic fatty liver diseases (NAFLD), through the gut-liver axis. To date, clinical guidelines recommend a weight loss goal of 7 to 10% to improve features… Continue reading →

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. While pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fa… Continue reading →

Colonoscopy is performed routinely for colorectal cancer (CRC) screening, follow-up of other abnormal screening tests, workup of signs and symptoms of gastrointestinal disease, and surveillance after CRC and polyp removal. Post procedure, colonoscopist… Continue reading →

The recently released fourth edition of Principles and Practice of Surgery for the Colon, Rectum, and Anus is designed to be a “comprehensive textbook that would encompass the gamut of colon and anorectal surgery.” This latest edition is 950 pages, plu… Continue reading →

Vanderbilt University biochemist Stanley Cohen, PhD, whose discovery of epidermal growth factor (EGF) and its receptor earned him a Nobel Prize and opened the door to a new class of cancer therapies, died Wednesday, Feb. 5, in Nashville. He was 97. Continue reading →